Susanna M. Kharit

Saint Petersburg, SPE, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.

Journal: Human vaccines & immunotherapeutics

Published: January 05, 2026

Acute Flaccid Paralysis in a Vaccinated Child With Primary Immunodeficiency: Difficulties With Diagnostics of Vaccine-Associated Paralytic Poliomyelitis.

Acute Flaccid Paralysis in a Vaccinated Child With Primary Immunodeficiency: Difficulties With Diagnostics of Vaccine-Associated Paralytic Poliomyelitis.

Journal: Journal of medical virology

Published: July 18, 2025

Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children.

Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children.

Journal: World journal of clinical pediatrics

Published: June 24, 2025

Anti-vaccine antibodies against measles, rubella, parotitis and hepatitis B in children with inflammatory bowel disease and healthy controls.

Anti-vaccine antibodies against measles, rubella, parotitis and hepatitis B in children with inflammatory bowel disease and healthy controls.

Journal: World journal of clinical pediatrics

Published: December 31, 2024

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

Journal: F1000Research

Published: November 01, 2022

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.

Journal: Human vaccines & immunotherapeutics

Published: October 27, 2021

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.

Journal: Human vaccines & immunotherapeutics

Published: September 02, 2021

The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study.

The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study.

Journal: Pediatric rheumatology online journal

Published: January 12, 2021

Safety and Immunogenicity of Two Doses of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Indian and Russian Children Aged 9 to 17 Months.

Safety and Immunogenicity of Two Doses of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Indian and Russian Children Aged 9 to 17 Months.

Journal: Indian pediatrics

Published: February 13, 2019

Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.

Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.

Journal: Vaccine

Published: May 05, 2017

PRINCIPLES OF MONITORING OF ADVERSE EVENTS AFTER VACCINATION IN RUSSIAN FEDERATION AND THE WORLD

PRINCIPLES OF MONITORING OF ADVERSE EVENTS AFTER VACCINATION IN RUSSIAN FEDERATION AND THE WORLD

Journal: Zhurnal mikrobiologii, epidemiologii i immunobiologii

Published: January 01, 2017

Burden of Childhood Rotavirus Disease in the Outpatient Setting of the Russian Federation.

Burden of Childhood Rotavirus Disease in the Outpatient Setting of the Russian Federation.

Journal: The Pediatric infectious disease journal

Published: December 21, 2016

Showing 1-12 of 16

Last Updated: 09/26/2026